- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07843225
Standard Closure vs. Integrated Mesh-Fascial Closure (IMFC) for Incisional Hernia Repair (IMFC)
Prospective Comparative Evaluation of the Integrated Mesh-Fascial Closure (IMFC) Technique Versus Standard Closure of the Abdominal Wall: A Quasi-Experimental, Non-Randomized Study
This study compares two surgical techniques for closing the abdominal wall in adult patients who have an incisional hernia (a weakness or opening in a previous surgical incision) or who require prophylactic mesh placement during a laparotomy.
In one group, the abdominal wall is closed using the standard technique, in which a polypropylene mesh is fixed independently from the fascial suture. In the other group, Integrated Mesh-Fascial Closure (IMFC) is used, a standardized execution of the technique of mesh incorporation into the fascial closure described by Jamal et al (Hernia, 2013).
The choice of technique is made by the patient after receiving information about both options and providing informed consent. Participants will be followed clinically and with imaging for 18 to 24 months to evaluate the safety, technical feasibility, and reproducibility of the IMFC technique, and to determine the incidence of hernia recurrence in both groups.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Incisional hernia is one of the most frequent complications of abdominal surgery, with a reported incidence of 10-20% after laparotomy, and recurrence rates after mesh repair reaching 20-30% in long-term follow-up. In conventional techniques, primary fascial closure and mesh fixation are performed as two mechanically independent steps, concentrating tension on the suture line during the acute postoperative period.
The Integrated Mesh-Fascial Closure (IMFC) technique integrates a macroporous polypropylene mesh within a continuous fascial suture line (pattern: mesh → right fascial edge → left fascial edge → mesh), aiming to distribute tensile load simultaneously between the fascia and the prosthesis, potentially reducing the incidence of hernia recurrence compared to standard closure. The principle of incorporating the mesh into the fascial closure was described by Jamal et al in a retrospective series of 72 patients. IMFC standardizes its execution (suture material, 5-mm bites in mesh and fascia, anchoring of the suture line in healthy aponeurosis, and optional minimal peripheral fixation) and evaluates it prospectively against standard closure.
This is a prospective, comparative, quasi-experimental (non-randomized) study conducted at a single center (Hospital Zonal General de Agudos "Dr. Mario V. Larrain," Berisso, Argentina). Eligible patients choose, after informed consent, between standard mesh closure (Group A) or IMFC (Group B). Both groups follow the same clinical and imaging follow-up schedule (days 7, 15, 30; months 2, 6, 12, 18; and a final visit between 18 and 24 months).
The study is designed as an initial, hypothesis-generating comparison of safety, technical feasibility, and reproducibility across surgeons, intended to support a future randomized trial.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Facundo B Mattano, MD
- Número de teléfono: +54 9 221 611-7976
- Correo electrónico: mattanofacundo@outlook.com
Copia de seguridad de contactos de estudio
- Nombre: Emiliano D Gargiulo, MD
- Número de teléfono: +54 2215371371
Ubicaciones de estudio
-
-
Buenos Aires
-
Berisso, Buenos Aires, Argentina, 1923
- Reclutamiento
- Hospital Zonal General de Agudos "Dr. Mario V. Larrain
-
Contacto:
- Facundo B Mattano, MD
- Número de teléfono: +54 9 2216117976
- Correo electrónico: mattanofacundo@outlook.com
-
Contacto:
- Emiliano D Gargiulo, MD
- Número de teléfono: +54 9 221 5371371
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults older than 18 years of age
- Patients with incisional (ventral) hernia
- Patients with recurrent incisional hernia
- Incisional hernias with a diameter greater than 4 cm
- Patients undergoing laparotomy with an indication for prophylactic mesh placement
Exclusion Criteria:
- Active surgical site infection
- Overt abdominal contamination
- Tissue necrosis or inability to achieve primary fascial closure
- Non-correctable loss of domain
- Pregnant women or women of childbearing potential planning pregnancy or not using contraception during the follow-up period
- Patients belonging to vulnerable populations, in accordance with Law 15.462 and applicable ethical guidelines
- Active oncologic disease (patients with a cured oncologic history may be included)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Standard Mesh Closure
Conventional fascial closure using a macroporous polypropylene mesh fixed independently from the closure suture |
Macroporous polypropylene mesh (FILAPROP™/MERIGROW™) plus non-absorbable polypropylene suture, placed using the conventional (independent) technique. |
|
Experimental: Integrated Mesh-Fascial Closure - IMFC
Fascial closure using the Integrated Mesh-Fascial Closure (IMFC) technique: the mesh is incorporated within the trajectory of a single continuous fascial suture (pattern: mesh → right fascial edge → left fascial edge → mesh |
Same materials integrated into a single continuous suture line using the IMFC technique. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recurrence rate of incisional hernia
Periodo de tiempo: 18-24 months (final follow-up visit)
|
Proportion of participants with hernia recurrence, assessed by clinical physical examination and abdominal wall ultrasound, performed in all participants at 6 months and at the final visit (18-24 months). All ultrasound evaluations performed by the same sonographer throughout the study; the sonographer is aware of study participation but blinded to the specific surgical technique (IMFC vs. standard closure) received by each participant. |
18-24 months (final follow-up visit)
|
|
Rate of Major Intraoperative and Postoperative Complications
Periodo de tiempo: Throughout study participation (up to 24 months)
|
Proportion of participants experiencing a serious adverse event (SAE), defined per ICH E6(R3) as death, a life-threatening event, hospitalization or prolongation of hospitalization, persistent or significant disability, or an unplanned surgical reintervention. Postoperative complications additionally graded using the Clavien-Dindo classification system (Grade I-V) to assess severity. |
Throughout study participation (up to 24 months)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Operative time and fascial closure time
Periodo de tiempo: Intraoperative (during the surgical procedure)
|
Total operative time (from skin incision to skin closure) and fascial closure time (from start to completion of the mesh-fascial suture line), both measured in minutes and recorded intraoperatively by the surgical team using the operating room clock. |
Intraoperative (during the surgical procedure)
|
|
Postoperative Pain Assessed by the 0-10 Numeric Pain Rating Scale (NRS-11)
Periodo de tiempo: Postoperative days 7, 15, and 30
|
Self-reported postoperative pain intensity measured using the 11-point Numeric Pain Rating Scale (NRS-11), an unabbreviated verbally- or visually-administered numeric scale ranging from 0 to 10, where 0 indicates "no pain" and 10 indicates "worst pain imaginable." Higher scores indicate worse (more severe) pain. Assessed at rest. |
Postoperative days 7, 15, and 30
|
|
Rate of Early Postoperative Complications (Infection, Seroma, Dehiscence, Hematoma)
Periodo de tiempo: Up to 30 days postoperative
|
Proportion of participants with surgical site infection, seroma, wound dehiscence, or hematoma, identified by clinical examination at scheduled postoperative visits (days 7, 15, and 30) and graded according to the Clavien-Dindo classification. |
Up to 30 days postoperative
|
|
Total Direct Hospital Costs (ARS) Associated with Complications or Reoperations
Periodo de tiempo: Up to 24 months (exploratory)
|
Total direct hospital costs, expressed in Argentine pesos (ARS), attributable to management of complications or unplanned reoperations, extracted from institutional administrative and billing records. Exploratory outcome; not powered for formal statistical comparison between groups. |
Up to 24 months (exploratory)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Facundo B Mattano, MD, Hospital Zonal General de Agudos "Dr. Mario V. Larrain
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Complicaciones Postoperatorias
- Procesos Patológicos
- Condiciones Patológicas, Anatómicas
- Hernia
- Hernia Abdominal
- Condiciones Patológicas, Signos y Síntomas
- Hernia incisional
- Hernia Ventral
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Hormonas hipotalámicas
- Hormonas peptídicas
- Neuropéptidos
- Péptidos
- Aminoácidos, péptidos y proteínas
- Proteínas del tejido nervioso
- Proteínas
- Hormonas pituitarias
- Hormonas pituitarias, anterior
- Melanocortinas
- Pro-Opiomelanocortina
- Hormonas estimuladoras de melanocitos
Otros números de identificación del estudio
- IMFC-HL-2026
- DISPO-2026-226-GDEBA-DIYCTMSAL (Otro identificador: Comisión Conjunta de Investigaciones en Salud (CCIS))
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .